SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 260 filers reported holding SAGE THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 2.05 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $533,331 | -56.2% | 25,915 | 0.0% | 0.01% | -52.4% |
| Q2 2023 | $1,218,523 | +12.0% | 25,915 | -0.1% | 0.02% | +5.0% |
| Q1 2023 | $1,088,442 | +10.0% | 25,940 | 0.0% | 0.02% | +5.3% |
| Q4 2022 | $989,352 | -2.6% | 25,940 | 0.0% | 0.02% | -13.6% |
| Q3 2022 | $1,016,000 | +21.1% | 25,940 | -0.2% | 0.02% | +22.2% |
| Q2 2022 | $839,000 | -2.4% | 25,990 | 0.0% | 0.02% | +20.0% |
| Q1 2022 | $860,000 | -22.2% | 25,990 | 0.0% | 0.02% | -16.7% |
| Q4 2021 | $1,106,000 | -4.0% | 25,990 | -0.0% | 0.02% | -10.0% |
| Q3 2021 | $1,152,000 | -20.9% | 26,000 | +1.4% | 0.02% | -28.6% |
| Q2 2021 | $1,457,000 | -24.1% | 25,650 | 0.0% | 0.03% | -28.2% |
| Q1 2021 | $1,920,000 | -13.6% | 25,650 | -0.1% | 0.04% | -15.2% |
| Q4 2020 | $2,221,000 | +41.6% | 25,675 | 0.0% | 0.05% | +24.3% |
| Q3 2020 | $1,569,000 | +46.6% | 25,675 | -0.2% | 0.04% | +42.3% |
| Q2 2020 | $1,070,000 | +46.8% | 25,725 | +1.3% | 0.03% | +23.8% |
| Q1 2020 | $729,000 | -60.3% | 25,400 | 0.0% | 0.02% | -51.2% |
| Q4 2019 | $1,834,000 | -48.5% | 25,400 | 0.0% | 0.04% | -51.7% |
| Q3 2019 | $3,563,000 | -23.4% | 25,400 | -0.1% | 0.09% | -27.0% |
| Q2 2019 | $4,654,000 | +15.1% | 25,417 | 0.0% | 0.12% | +11.9% |
| Q1 2019 | $4,043,000 | +66.2% | 25,417 | +0.1% | 0.11% | +45.3% |
| Q4 2018 | $2,433,000 | -26.4% | 25,400 | +8.5% | 0.08% | -19.4% |
| Q3 2018 | $3,305,000 | -9.8% | 23,400 | 0.0% | 0.09% | -16.2% |
| Q2 2018 | $3,663,000 | -2.8% | 23,400 | 0.0% | 0.11% | -4.3% |
| Q1 2018 | $3,769,000 | +19.7% | 23,400 | +22.4% | 0.12% | +23.4% |
| Q4 2017 | $3,148,000 | +222.2% | 19,111 | +21.8% | 0.09% | +213.3% |
| Q3 2017 | $977,000 | +26.7% | 15,687 | +61.9% | 0.03% | +25.0% |
| Q2 2017 | $771,000 | -0.4% | 9,687 | -11.0% | 0.02% | 0.0% |
| Q1 2017 | $774,000 | +84.7% | 10,884 | +32.8% | 0.02% | +71.4% |
| Q4 2016 | $419,000 | +11.1% | 8,197 | 0.0% | 0.01% | +7.7% |
| Q3 2016 | $377,000 | – | 8,197 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Casdin Capital, LLC | 312,000 | $29,886,000 | 5.11% |
| DAFNA Capital Management LLC | 104,306 | $9,991,000 | 4.97% |
| Palo Alto Investors LP | 850,977 | $81,515,000 | 4.34% |
| BB BIOTECH AG | 1,375,229 | $131,733,000 | 4.22% |
| Eventide Asset Management | 936,000 | $89,659,000 | 3.97% |
| TRV GP II, LLC | 37,362 | $3,579,000 | 3.56% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 146,179 | $14,002,000 | 2.11% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 111,908 | $10,720,000 | 2.06% |
| OAK RIDGE INVESTMENTS LLC | 231,483 | $22,174,000 | 1.60% |
| Rhenman & Partners Asset Management AB | 137,339 | $13,156,000 | 1.50% |